Core Viewpoint - The company has approved the use of part of the raised funds to permanently supplement its working capital, which is expected to enhance the efficiency of fund utilization and reduce financial costs [10][15][16]. Group 1: Supervisory Board Meeting - The sixth meeting of the fourth supervisory board was held on September 5, 2025, with all three supervisors present, and the meeting was conducted in accordance with relevant laws and regulations [1][3]. - The supervisory board approved the proposal to use part of the raised funds, amounting to RMB 156 million, to permanently supplement working capital, which constitutes 29.87% of the total raised funds [10][12]. - The proposal will be submitted to the shareholders' meeting for approval [4][7]. Group 2: Fund Utilization - The company plans to use RMB 156 million of the raised funds for working capital, which will not affect the funding needs of investment projects and will not involve high-risk investments within the next 12 months [10][12]. - The total amount of raised funds was RMB 1,226.34 million, with a net amount of RMB 1,085.40 million after deducting related fees [10][11]. - The company has committed to not exceeding 30% of the total raised funds for working capital supplementation within any twelve-month period [12][13]. Group 3: Governance Changes - The company has decided to abolish the supervisory board and transfer its responsibilities to the audit committee of the board of directors, which will also involve amendments to the company’s articles of association [40][41]. - The company plans to change its business scope by removing "first-class value-added telecommunications services" from its operations [40]. - The board of directors has proposed to increase the number of directors from 6 to 8, including the addition of one independent director and one employee representative director [18][19].

Group 1 - The company held its sixth meeting of the fourth Supervisory Board on September 5, 2025, via telecommunication, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to use part of the raised funds to permanently supplement working capital, which is deemed to meet the company's liquidity needs and improve the efficiency of fund usage [1][2] - The proposal received unanimous support with 3 votes in favor, requiring submission to the shareholders' meeting for further approval [2] Group 2 - The Supervisory Board also approved the proposal to cancel the Supervisory Board, change the business scope, and amend the company's articles of association, which will also be submitted to the shareholders' meeting [2]

Core Viewpoint - The company is convening its first extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the use of excess raised funds to supplement working capital and the reappointment of an accounting firm for financial auditing [6][8]. Group 1: Meeting Procedures - The meeting will follow a structured agenda, allowing shareholders to exercise their rights, including speaking, questioning, and voting [2][3]. - Shareholders must register and present necessary identification documents to participate in the meeting [1][2]. - Voting will be conducted through both on-site and online methods, with specific time frames for each [4][6]. Group 2: Proposals - Proposal 1 involves using CNY 72 million (approximately USD 10.1 million) of excess raised funds to permanently supplement working capital, which represents 29.73% of the total excess funds raised of CNY 242.2 million (approximately USD 34.1 million) [6][8]. - Proposal 2 seeks to reappoint Rongcheng Accounting Firm for the 2025 financial audit, with an audit fee of CNY 700,000 (approximately USD 98,000), maintaining the same fee as the previous year [8][12].

Core Viewpoint - The company plans to use part of the excess raised funds, amounting to RMB 47 million, to permanently supplement its working capital, which is expected to enhance operational efficiency and profitability while ensuring compliance with relevant regulations [5][6][8]. Fundraising Overview - The company successfully issued 30 million shares at a price of RMB 76.80 per share, raising a total of RMB 230.4 million, with a net amount of RMB 210.69 million after deducting issuance costs. The excess funds amounted to RMB 157.6 million [2][3]. Fund Usage - The company has adjusted its fundraising project allocations, reducing investments in the "Headquarters Project" and "Anhui Construction Project" to allocate funds to a new project, the "Huai'an Intelligent Equipment Production Base Project" [4][5]. Previous Use of Excess Funds - As of the announcement date, the company has used a total of RMB 94 million of excess funds to permanently supplement working capital, leaving a balance of RMB 63.6 million [5][6]. Justification for Current Fund Usage - The decision to use RMB 47 million of excess funds is based on the need to meet working capital requirements, improve fund utilization efficiency, and enhance profitability, all while ensuring that the fundraising projects remain unaffected [6][7]. Decision-Making Process - The board and supervisory committee have approved the use of excess funds, confirming that it aligns with regulatory requirements and does not harm shareholder interests. The matter is set to be submitted for shareholder approval [7][8].

Core Viewpoint - The company plans to permanently supplement its working capital with the remaining over-raised funds of RMB 5,072.57 thousand from its initial public offering (IPO) project, which requires approval from the shareholders' meeting [1][5][6] Fundraising Basic Situation - The company raised a total of RMB 119,000.00 thousand from the IPO by issuing 68 million shares at a price of RMB 17.50 per share, with a net amount of RMB 106,247.08 thousand after deducting issuance costs of RMB 12,752.92 thousand [1][2] Investment Project Situation - The net amount raised from the IPO was planned to be invested in specific projects, with a total investment amount of RMB 100,000.00 thousand [2] Use of Over-raised Funds - The company has used over-raised funds for share repurchase, with a total repurchase amount of RMB 138,809,738.95, of which RMB 70,135,413.12 was from over-raised funds [3][4] - As of June 30, 2025, the remaining over-raised funds amounted to RMB 5,072.57 thousand, primarily from interest income and cash management product returns [4][5] Remaining Over-raised Funds Usage Plan - The company plans to use RMB 5,072.57 thousand of the remaining over-raised funds to permanently supplement working capital, which is within the regulatory limits set by the China Securities Regulatory Commission and the Shanghai Stock Exchange [4][5][6] Related Explanation and Commitment - The company commits that the cumulative amount used to supplement working capital within 12 months will not exceed 30% of the total over-raised funds [5]

Fundraising Overview - The company raised a total of RMB 119 million from its initial public offering (IPO), with a net amount of RMB 106.25 million after deducting issuance costs of RMB 12.75 million [1] - The IPO involved the issuance of 68 million shares at a price of RMB 17.50 per share [1] Investment Project Status - The net amount raised is planned to be invested in specific projects totaling RMB 100 million, with adjustments made to the expected operational status dates for several projects [2] - The project "New Generation Laser Display Product R&D and Industrialization" is now expected to reach operational status by December 2022, while the "Headquarters R&D Center Project" and "Information System Upgrade Project" have been postponed to March 2025 [2] Use of Excess Funds - The company has approved the use of excess funds for share repurchase, with a total repurchase amount not less than RMB 10 million and not exceeding RMB 20 million, at a price not exceeding RMB 26.89 per share [3][4] - As of June 30, 2025, the total excess funds amount to RMB 70.14 million, with RMB 5.07 million planned for permanent working capital supplementation [5] Board and Supervisory Committee Approval - The board of directors approved the use of excess funds for permanent working capital on August 28, 2025, pending shareholder approval [6] - The supervisory committee also reviewed and agreed that the use of excess funds for working capital would enhance fund utilization efficiency without significantly impacting normal operations [6] Sponsor's Verification Opinion - The sponsor, Huatai United Securities, confirmed that the use of excess funds for permanent working capital complies with relevant regulations and does not harm the interests of shareholders, particularly minority shareholders [7][8]

Core Viewpoint - Yunnan Betaini Biotechnology Group Co., Ltd. plans to use part of its raised funds to temporarily supplement working capital, addressing a temporary cash flow gap due to market changes [1][2]. Fundraising and Usage - The company raised a total of 3,636 million shares at a price of 47.33 yuan per share, totaling 3,010 million yuan, with a net amount of 2,884 million yuan after deducting issuance costs [1]. - The total investment for projects funded by the raised capital is 1,535 million yuan, with excess funds amounting to 1,349 million yuan [1]. - Previous arrangements for the use of excess funds include: - 2021: 400 million yuan for permanent working capital [2]. - 2023: Up to 320 million yuan for temporary working capital, fully repaid by August 8, 2024 [2]. - 2024: 360 million yuan for the "Betaini Central Factory Phase II Project" [2]. - 2024: Up to 320 million yuan for temporary working capital, fully repaid by August 14, 2025 [2]. - 2025: Up to 700 million yuan of idle raised funds and 2,500 million yuan of idle self-owned funds for cash management [2]. - As of August 14, 2025, the balance of excess funds was 325 million yuan, with 340 million yuan allocated for cash management [2]. Board Approval and Compliance - The proposal to use up to 320 million yuan of excess funds for temporary working capital has been reviewed and approved by the audit committee and independent directors, confirming compliance with relevant regulations [3]. - The sponsoring institution, Guosen Securities Co., Ltd., has no objections to this matter [3].

Core Points - The board of directors of Rongxin Education and Cultural Industry Development Co., Ltd. held its eighth meeting of the fourth session on August 26, 2025, to discuss various proposals [1][2][3]. Group 1: Meeting Details - The meeting was convened by Chairwoman Wang Yihua and attended by all 8 directors, with senior management present [1]. - The meeting complied with relevant laws, regulations, and the company's articles of association [1]. Group 2: Resolutions Passed - The board approved the proposal regarding the 2025 semi-annual report and summary, confirming the accuracy and completeness of financial information [2]. - The board also approved a special report on the management and use of raised funds for the first half of 2025, confirming compliance with regulations [2]. - A proposal to amend the company's articles of association was approved, with authorization for management to handle subsequent registration matters [3]. - The board approved the proposal to revise corporate governance-related systems, which will also require shareholder approval [5]. - A proposal to use part of the excess raised funds to permanently supplement working capital was approved, pending shareholder approval [6]. - The board scheduled the second extraordinary general meeting of shareholders for September 15, 2025 [6]. Group 3: Voting Results - All proposals received unanimous support with 8 votes in favor, and no votes against or abstentions [2][3][5][6]. Group 4: Reference Documents - The company disclosed relevant documents on the Giant Tide Information Network, including the meeting resolutions and audit committee decisions [6].

Core Viewpoint - Suzhou Nearshore Protein Technology Co., Ltd. plans to use part of its oversubscribed funds amounting to RMB 72 million for permanent working capital, which represents 29.73% of the total oversubscribed funds, pending approval from the shareholders' meeting [1][5]. Fundraising Overview - The company raised a net amount of RMB 1,742.20 million from its initial public offering, with total oversubscribed funds amounting to RMB 242.20 million [2][4]. - The total investment amount for the fundraising projects is RMB 1,500 million, with the planned use of funds from this issuance also being RMB 1,500 million [2]. Plan for Using Oversubscribed Funds - The decision to use RMB 72 million of the oversubscribed funds for working capital is aimed at meeting the company's liquidity needs and improving the efficiency of fund usage, while ensuring that the fundraising projects continue as planned [2][3]. - The company commits that the cumulative use of oversubscribed funds for permanent working capital will not exceed 30% of the total oversubscribed funds within any twelve-month period [3][4]. Review and Approval Process - The board of directors and the supervisory board have approved the proposal to use part of the oversubscribed funds for working capital, which will be submitted for further approval at the shareholders' meeting [5]. - The supervisory board believes that the decision complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5].

Core Viewpoint - The company plans to use part of the excess raised funds, amounting to 72 million RMB, to permanently supplement its working capital, which aligns with its business development needs and aims to enhance profitability while protecting shareholder interests [3][5]. Fundraising Overview - The company successfully completed its initial public offering (IPO) on September 26, 2022, raising a total of 1,742.1958 million RMB, with a total excess of 242.1958 million RMB after deducting issuance costs [1][2]. - The total investment amount for the core diagnostic raw materials and innovative diagnostic reagents industrialization project is 1,500 million RMB, which will utilize the raised funds [2]. Use of Excess Funds - The company intends to allocate 72 million RMB, which is 29.73% of the total excess funds, to permanently supplement working capital, ensuring that the funding needs for investment projects are met [3][4]. - The cumulative use of excess funds for working capital will not exceed 30% of the total excess funds within the last 12 months, complying with regulatory requirements [4]. Impact on Daily Operations and Commitments - The company commits that the use of excess funds will not affect the funding needs of investment projects and will refrain from high-risk investments or providing financial assistance to entities outside its controlling subsidiaries within the next 12 months [4][5]. - The supervisory board supports the decision, stating that it meets regulatory requirements and does not harm the interests of shareholders, particularly minority shareholders [5]. Review Process and Opinions - The proposal to use part of the excess funds was approved in nine meetings and will be submitted for shareholder approval [5]. - The sponsor institution has verified that the use of excess funds for working capital will enhance efficiency and reduce financial costs without affecting the normal progress of investment projects [5].